Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by certain officers and directors of Cell Therapeutics, Inc. ("Cell Therapeutics" or the "Company") (NASDAQ: CTIC). Cell Therapeutics develops, acquires, and commercializes oncology products for the treatment of cancer. The Company was founded in 1991 and is headquartered in Seattle, Washington.

Robbins Umeda LLP's investigation concerns whether the Company's directors and officers caused the Company to issue materially false and misleading statements. Specifically, the investigation will determine whether these directors and officers misrepresented the efficacy and safety of one of the Company's products, Pixantrone.

In addition, certain of Cell Therapeutics' officers and directors may have also failed to ensure that the Company's Pixantrone trials complied with the U.S. Food and Drug Administration's Special Protocol Assessment by which the drug was tested. Possible violations of the special protocol include not enrolling an adequate amount of patients with aggressive non-Hodgkin's lymphoma.

A lawsuit alleging violations of the Securities Exchange Act of 1934 has been filed on behalf of shareholders who purchased or otherwise acquired Cell Therapeutics stock between May 5, 2009 and February 8, 2010, against the Company and certain of its officers. Securities class actions like this can potentially cause additional damage to the Company.

If you purchased your Cell Therapeutics stock prior to May 5, 2009, continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Lauren Levi at 800-350-6003 or by e-mail at llevi@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm, which has significant experience representing investors in shareholder derivative actions, securities fraud class actions, and merger-related shareholder class actions. For more information about the firm, please go to http://www.robbinsumeda.com.

Advertisement

Copyright Business Wire 2010